Scott Clarke

Scott Clarke brings with him more than 20 years of experience in the biotechnology and pharmaceutical industry.

Scott most recently served as CEO of Trishula Therapeutics. He was responsible for launching Trishula - out of Tizona Therapeutic’s transaction with Gilead Sciences - as a stand-alone, thriving company.

Previously, Scott served as Tizona’s Chief Executive Officer. Under his leadership, Tizona’s two lead programs advanced into the clinic, the company built out its preclinical portfolio, and entered into a transformational alliance with Gilead. He continues to serve on the Board of Directors of both Trishula and Tizona.

Prior to Tizona, Scott served as Global Head of Oncology Partnering and Head of Asia and Emerging Markets Partnering at Roche. In this role he was responsible for licensing, clinical collaborations, and acquisitions in oncology, and for sourcing opportunities across all indications from Asia.

From 2005 to 2017, Scott held positions of increasing responsibility at BioMarin, including serving as the Senior Vice President of Product Development, responsible for advancing BioMarin’s portfolio of clinical and late preclinical product candidates through approval. Prior to this role, Scott was Vice President of Business Development and Scientific Licensing overseeing all preclinical and early clinical licensing and M&A.

Scott earned a Bachelor of Science in Chemical Engineering from the University of California, Berkeley, a Master of Science in Biotechnology at Northwestern University and an MBA from London Business School.